Over a billion people around the world are at high risk of blindness from diseases such as glaucoma and diabetic retinopathy. And yet more than 75% of these people do not receive regular screenings, even though early detection is the key to saving patients’ vision. Aireen is an AI-based computer diagnostic medical device that simplifies the screening process by removing the ophthal- mological middleman to providing early diagnostics of several chronic diseases using fundus pictures of eye retina. Comprehensive results are provided by Aireen in less than 30 seconds. It is a non-invasive, painless screening and a cost-effective method based solely on eye retina digital images. Aireen automates and rapidly expedites diagnostic processes, reduces costs and also works ideally with regard to social distancing. It doesn't require a specialist optician to operate or make a diagnosis, reducing the need to see additional doctors. The Aireen team is creating a unique, AI-based system that is fundus camera vendor agnostic to ensure patients who need an eye checkup can receive sensitive and accurate screening of multiple chronic diseases, through the analysis of fundus pictures of eye retina, without having to wait until their next visit to the ophthalmolo-gist’s office. Starting with support of major diseases like diabetic retinopathy, followed by AMD (age-related macular degeneration) disease and glaucoma. In light of the promising results of the Aireen AI diagnostic engine, we are among the first projects in the world to begin researching the early detection of Alzheimer’s disease using this technology. The reason for this is that only one in four people with Alzheimer’s disease has been diagnosed. Our ambition is to detect Alzheimer’s disease from eye retina earlier than present diagnostics methods are able to do. Aireen aims to extend competence of non-ophthalmologic medical providers by adding new diagnoses to improve patients' access to screening and early diagnostics without the need for additional visits to the ophthalmologist. Through this process, Aireen will enable significant costs savings in the healthcaresystem. Aireen is an offcially registered medical device and currently on track to receive our MDR IIa by the end of 2022. In the later stage of expansion, we will apply for FDA approval. We already have several exciting projects in the pipeline, ready for launch as soon as we get the clearance to detect retinal conditions, prevent blindness and save lives. The development of Aireen is happening in close cooperation with several prestigious health organisations and universities, such as the Ophthalmology Clinic of the Military University Hospital in Prague, NeoVize Group and OCP Praha.
Prague, Praha, Hlavni mesto, 11000
Artificial Intelligence : Medical imaging, Analysis and Diagnostics
Health and Life Sciences : Medical Devices
Resource Type: Thumbnail Image
Resource Type: Articles